Peptides et Protéines
Les peptides sont de courtes chaînes d'acides aminés reliées par des liaisons peptidiques, tandis que les protéines sont des chaînes d'acides aminés plus longues et complexes pouvant adopter des structures tridimensionnelles fonctionnelles. Ces deux types de composés sont essentiels à diverses fonctions biologiques, comme la catalyse des réactions (enzymes), la défense immunitaire (anticorps) et la signalisation cellulaire. Les protéines ont une structure hiérarchique comprenant la séquence d’acides aminés, ainsi que les structures secondaire, tertiaire et quaternaire. Les peptides sont utilisés dans les thérapies pharmaceutiques et cosmétiques pour leurs propriétés biologiques spécifiques, notamment dans le traitement des maladies métaboliques ou l’amélioration de la régénération cellulaire. Les protéines, quant à elles, ont des applications en biotechnologie, en nutrition et en médecine régénérative.
Chez CymitQuimica, nous proposons des peptides et des protéines de haute pureté pour la recherche en biotechnologie et les applications thérapeutiques.
3159 produits trouvés pour "Peptides et Protéines"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tert-butyl Acetate
CAS :Produit contrôlé<p>Applications Tert-butyl Acetate is a common solvent used in the production of various industrial cleansers, thinners and adhesives and is also known as a VOC.Environmental contaminants; Food contaminants<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Mackay, D., et al.: SAR. QSAR. Enviro. Res., 23, 205 (2012); Yang, Y.S., et al.: Toxicol. Res., 26, 293 (2010);<br></p>Formule :C6H12O2Couleur et forme :ColourlessMasse moléculaire :116.16Lopinavir Metabolite M-1
CAS :Produit contrôlé<p>Applications A major metabolite of Lopinavir (L469480) . It is a COVID19-related research product.<br>References Molla, A., et al.: J. Virology, 250, 255 (1998), Sham, H., et al.: Antimicrob. Agents Chemother., 42, 3218 (1998), Kumar, G., et al.: Drug Metab. Dispos., 27, 86 (1999),<br></p>Formule :C37H46N4O6Couleur et forme :NeatMasse moléculaire :642.78Carbetocin
CAS :<p>Applications An obstetric drug used to control postpartum hemorrhaging.<br>References Sanz-Nebot, V., et al.: Anal. Bioanal. Chem., 377, 306 (2003), Gimpl, G., et al.: Eur. J. Pharmacol., 510, 9 (2005), Handler, J., et al.: Theriogenol., 66, 1397 (2006), Klenerova, V., et al.: J. Physiol. Pharmacol., 60, 57 (2009),<br></p>Formule :C45H69N11O12SCouleur et forme :NeatMasse moléculaire :988.16L-Methionine
CAS :<p>Applications Essential aminoacid for human development. Hepatoprotectant; antidote (acetominophen poisoning); urinary acidifier.<br>References Benevenga, N.J., et al.: J. Agric. Food Chem., 22, 2 (1974), Fleisher, L.D., et al.: Clin. Endocrinol. Metab., 3, 37 (1974), Meinnel, T., et al.: Biochimie, 75, 1061 (1993),<br></p>Formule :C5H11NO2SCouleur et forme :White To Off-WhiteMasse moléculaire :149.21Desethyl Sacubitril-d4
CAS :Produit contrôléFormule :C22H21D4NO5Couleur et forme :NeatMasse moléculaire :387.46Semaglutide Impurity 101 (D-Glu 3)
D-Glu(3)-Semaglutide is a semaglutide impurity. The amino acid at position 3 has been replaced by the D-form of the amino acid D-glutamic acid (D-Glu). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molD-Phe(6)-Semaglutide
<p>D-Phe(6)-Semaglutide is a semaglutide impurity. The amino acid at position 6 has been replaced by the D-form of the amino acid D-phenylalanine (D-Phe). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molLisinopril EP Impurity E
CAS :Lisinopril EP Impurity E is an impurity of lisinopril, which is a prescription drug used to treat high blood pressure. This impurity was found in a preparative high performance liquid chromatography (HPLC) and mass spectroscopy analysis of the drug. The molecular weight of Lisinopril EP Impurity E was determined to be 317.2 amu, which corresponds to the molecular formula C7H13NO2. The FT-IR spectrum showed that this impurity has an ammonium group at 1859 cm-1 and butanoic acid at 1647 cm-1.Formule :C21H31N3O5Degré de pureté :Min. 98 Area-%Couleur et forme :PowderMasse moléculaire :405.49 g/mol3,3',5,5'-Tetraiodothyroformic acid
CAS :Cymit Quimicaetic beta-D-glucosiduronic acidFormule :C13H6I4O4Degré de pureté :Min. 95 Area-%Couleur et forme :Off-White PowderMasse moléculaire :733.8 g/molBortezomib intermediate I
CAS :Bortezomib intermediate I is a metabolite of bortezomib, which is a research and development drug product. Bortezomib intermediate I is an impurity standard for bortezomib. Bortezomib intermediate I can be synthesized from the corresponding compound. It is an analytical standard used in pharmacopoeia and can be used as an API impurity or synthetic material in drug development. Bortezomib intermediate I has a high purity, natural origin, and a niche application. CAS No. 1248339-44-7Formule :C25H36BN5O4Degré de pureté :Min. 95%Couleur et forme :White PowderMasse moléculaire :481.4 g/molD-Ser(8)-Semaglutide
<p>D-Ser(8)-Semaglutide is a semaglutide impurity. The amino acid at position 8 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molSemaglutide Impurity 29 (beta-Asp-9)
<p>Beta-Asp-(9)-Semaglutide is a semaglutide impurity. The amino acid at position 9 has been replaced by the beta-aspartic acid (also known as isoaspartic, isoAsp, β-Asp or beta-Asp). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molD-Val(10)-Semaglutide
<p>D-Val(10)-Semaglutide is a semaglutide impurity. The amino acid at position 10 has been replaced by the D-form of the amino acid D-valine (D-Val). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molD-His(1)-Semaglutide
D-His(1)-Semaglutide is a semaglutide impurity. The amino acid at position 1 has been replaced by the D-form of the amino acid D-histidine (D-His). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/mol(S,E)-N-(1-(3-Methylbut-1-enylamino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide
CAS :<p>R-N-(1-(3-methylbut-1-enyl)-1-oxo-3-phenylpropan-2-yl) pyrazine-2-carboxamide is a drug product that is used for the treatment of bacterial infections. The compound is an impurity in the synthesis of other compounds and is also used as an analytical standard. It is synthesized from commercially available starting materials and through custom synthesis. R-N-(1-(3-methylbut-1-enyl)-1--oxo--3--phenylpropan--2--yl)pyrazine--2--carboxamide has been shown to be metabolized by CYP450 enzymes, which are responsible for the metabolism of many drugs. R-(1-(3Methylbut 1Enylamino)-1Oxo 3Phenylpropan 2Yl)Pyrazine 2Carboxamide has not been evaluated as a drug product and therefore does not</p>Formule :C19H22N4O2Degré de pureté :Min. 95%Masse moléculaire :338.4 g/molD-Ser-(12)-Semaglutide
D-Ser(12)-Semaglutide is a semaglutide impurity. The amino acid at position 12 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molD-Thr(5)-Semaglutide
D-Thr(5)-Semaglutide is a semaglutide impurity. The amino acid at position 5 has been replaced by the D-form of the amino acid D-threonine (D-Thr). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molD-Ala-(19)-Semaglutide
<p>D-Ala(19)-Semaglutide is a semaglutide impurity. The amino acid at position 19 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molD-Ser(11)-Semaglutide
D-Ser(11)-Semaglutide is a semaglutide impurity. The amino acid at position 11 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molSemaglutide Impurity 54 (D-Ala 18)
<p>D-Ala(18)-Semaglutide is a semaglutide impurity. The amino acid at position 18 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formule :C187H291N45O59Masse moléculaire :4,113.64 g/mol
